Compare Broadcom Inc (AVGO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Broadcom Inc vs Merck & Co., Inc. — how do they compare? Broadcom Inc trades at $419.28 (market cap $1.98T), while Merck & Co., Inc. trades at $135.39 (market cap $327.94B). The key difference: Broadcom Inc is far larger — about 6× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.56%). Which is the better fit depends on your goals.
| AVGO | MRK | |
|---|---|---|
Market Cap | $1.98T | $327.94B |
Sector | Technology | Health |
52-Week High | $481.57 | $132.93 |
52-Week Low | $289.60 | $77.60 |
Enterprise Value | $2.02T | $374.70B |
Dividend Yield | 0.62% | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MRK trades at $135.55, up 3.91% today, near its consensus price target of $140.58. The stock shows bullish technical momentum with strong moving average signals, though RSI levels indicate potential overbought conditions. Recent earnings beats and a 67.57% analyst buy rating reflect positive sentiment. The acquisition of Terns Pharmaceuticals for approximately $6.7 billion (Business Wire, 2026-04-07) aims to bolster its oncology pipeline, while steady revenue growth and a 28.07% net income margin in 2025 underscore fundamental strength.
Outlook remains favorable with strategic M&A and earnings consistency, but risks include high valuation multiples (P/E of 106.34) and competitive pressures in pharma. The stock offers growth potential from pipeline expansion, yet investors face headwinds from debt increases and market volatility. Upside to the $155 high target depends on successful integration and sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
